Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Clin Cancer Res. 2017 Jun 19;23(17):5055–5065. doi: 10.1158/1078-0432.CCR-16-2946

Table 2.

Number of patients with adverse events following treatment

Adverse Event Grade
1 2 3
System Organ Class    Specific Term
Cardiac disorders    Tachycardia 0 2 0
Gastrointestinal disorders Any AE - Maximum 7 3 0
   Abdominal pain 2 2 0
   Constipation 1 1 0
   Diarrhea 1 0 0
   Nausea 7 0 0
   Vomiting 5 1 0
General disorders and administration site conditions Any AE - Maximum 2 0 0
   Fatigue 2 0 0
   Edema peripheral 1 0 0
   Pyrexia 1 0 0
Investigations Any AE - Maximum 3 0 1
   Alanine aminotransferase increased 1 0 0
   Aspartate aminotransferase increased 1 0 0
   Blood creatinine increased 3 0 0
   Hemoglobin decreased 0 0 1
Metabolism and nutrition disorders Any AE - Maximum 4 2 0
   Decreased appetite 3 0 0
   Hypercalcemia 0 1 0
   Hyperkalemia 0 1 0
   Hypocalcaemia 2 0 0
   Hypomagnesaemia 0 1 0
Musculoskeletal and connective tissue disorders Any AE - Maximum 1 1 0
   Flank pain 0 1 0
   Myalgia 1 0 0
Nervous system disorders    Dizziness 1 0 0
Renal and urinary disorders    Hematuria 1 0 0
Respiratory, thoracic and mediastinal disorders    Dyspnea 1 0 0
Vascular disorders    Hypotension 0 1 0
Injury, poisoning and procedural complications    Radiation skin injury 0 1 0
ANY AE - Maximum Grade Seen Total (percentage) 6 (37.5) 4 (25) 1 (6)